Axsome Therapeutics Inc AXSM shares are trading higher Tuesday after the company announced it received and agreed to Postmarketing Requirements/Commitments proposed by the U.S. Food and Drug Administration with respect to the New Drug Application (NDA) for its AXS-05.
AXS-05 is Axsome's product candidate for the treatment of major depressive disorder. The company anticipates potential FDA action on the NDA sometime in the second quarter.
Axsome Therapeutics is a biopharmaceutical company developing novel therapies for central nervous system conditions that have limited treatment options.
See Also: Morning Brief: Top Financial Stories Dominating on Tuesday, April 19
AXSM 52-Week Range: $19.38 - $74.10
According to data from Benzinga Pro, the stock was up 24.7% at $40.78.
Photo: jarmoluk from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
